What are the clinical treatment guidelines for wide‑complex tachycardia?

Clinical Treatment Guidelines for Wide Complex Tachycardia

Immediate Assessment: Hemodynamic Stability Determines Everything

If the patient shows ANY signs of hemodynamic instability (hypotension, altered mental status, chest pain, acute heart failure, or shock), perform immediate synchronized cardioversion without delay for any pharmacologic therapy or additional diagnostics. 1, 2, 3

• Sedate the conscious patient if time permits (etomidate 0.2-0.3 mg/kg IV is preferred in hypotensive patients) 2, 3
• Apply defibrillator pads immediately and have equipment ready 2
• A precordial thump may be considered for witnessed, monitored unstable VT if a defibrillator is not immediately ready (Class IIb) 1
• Do NOT delay cardioversion to obtain additional ECGs, correct electrolytes, or attempt pharmacologic conversion 2, 3

For Hemodynamically STABLE Wide Complex Tachycardia

Critical First Principle

Assume ALL wide complex tachycardia is ventricular tachycardia (VT) until proven otherwise—misdiagnosis can be fatal if treated as SVT. 3, 4

Step 1: Obtain 12-Lead ECG and Assess Rhythm Regularity 1, 2

• Record a 12-lead ECG during tachycardia (Class I recommendation) 1
• Determine if the rhythm is regular/monomorphic versus irregular/polymorphic 1, 2
• Check for QT prolongation on prior ECGs if available 1

Step 2: Management Based on Rhythm Type

For REGULAR Monomorphic Wide Complex Tachycardia:

First-line: IV Procainamide (Class IIa)

• Procainamide is the preferred agent for stable monomorphic VT in patients without severe heart failure or acute MI 1, 3
• Dose: 20-50 mg/min IV until arrhythmia suppression, hypotension, QRS widens by >50%, or maximum 17 mg/kg given 1
• Monitor blood pressure closely during infusion 3
• Avoid if QT is prolonged 1

Alternative: IV Amiodarone (Class IIb)

• Amiodarone 150 mg IV over 10 minutes is preferred if there is ANY concern for impaired left ventricular function, heart failure, or acute MI 1, 2, 3
• Amiodarone has a better safety profile in structural heart disease but is slower to convert than procainamide 3
• Can repeat 150 mg every 10 minutes as needed 2

Diagnostic/Therapeutic Option: IV Adenosine (Class IIb)

• Adenosine may be considered for undifferentiated regular stable wide complex tachycardia—it is relatively safe and can help diagnose the underlying rhythm 1, 2, 3
• Dose: 6 mg rapid IV push, followed by 12 mg if no response 3
• If the rhythm terminates with adenosine, this suggests SVT with aberrancy rather than VT 3
• Contraindications: Do NOT use for irregular or polymorphic wide complex tachycardia (can cause degeneration to VF), severe asthma, or known pre-excitation syndromes 1, 3

Third-line: IV Sotalol (Class IIb)

• Sotalol 1.5 mg/kg IV over 5 minutes may be considered 1, 2
• Avoid if QT is prolonged 1, 2

For IRREGULAR/Polymorphic Wide Complex Tachycardia:

If QT is prolonged (Torsades de Pointes):

• IV magnesium sulfate 2 grams IV push is the primary treatment 2, 3, 5
• Consider overdrive pacing or IV isoproterenol if accompanied by bradycardia or pauses 3, 5
• Discontinue all QT-prolonging medications 2
• Correct electrolytes (especially potassium >4.0 mEq/L, magnesium >2.0 mg/dL) 2, 5

If QT is normal (likely ischemic VT):

• IV amiodarone may be effective (Class IIb) 1
• IV beta-blockers may reduce arrhythmia recurrence if ischemia is suspected (Class IIb) 1, 3
• Immediate cardiology consultation for possible emergent catheterization 2

Critical Medications to AVOID

Absolutely contraindicated in wide complex tachycardia of unknown origin: 1, 3

• Calcium channel blockers (verapamil, diltiazem)—can cause hemodynamic collapse if the rhythm is VT (Class III) 1, 3
• Beta-blockers in hypotensive states 2, 3
• Adenosine for irregular or polymorphic wide complex tachycardia 1, 3

Do not combine:

• IV calcium channel blockers and beta-blockers together (potentiation of hypotension and bradycardia) 1
• Multiple antiarrhythmic agents without expert consultation (Class III) 1

Essential Concurrent Management

Electrolyte Correction (Critical Priority)

• Rapidly correct potassium (target >4.0 mEq/L), magnesium (target >2.0 mg/dL), and calcium abnormalities 2, 3, 5
• Stat electrolyte panel should be obtained immediately 2

Monitoring Requirements

• Continuous cardiac telemetry monitoring 2, 3
• Blood pressure monitoring every 5 minutes until stable 2
• Pulse oximetry with supplemental oxygen to maintain SpO2 >94% 2
• Serial 12-lead ECGs (baseline, post-intervention, then every 4-6 hours) 2

Diagnostic Workup

• Stat troponin, BNP, complete blood count, renal function 2
• Portable chest X-ray to assess for heart failure 2
• Echocardiogram once stabilized to assess ventricular function and structural disease (Class I) 1, 2

Disposition and Follow-up

All patients with wide complex tachycardia require: 2, 3

• ICU/CCU admission 2
• Immediate cardiology/electrophysiology consultation 1, 2, 3
• Consideration for electrophysiology study and possible catheter ablation once stabilized 1, 2, 3

Common Pitfalls to Avoid

• Never delay cardioversion in unstable patients to attempt pharmacologic conversion or obtain additional studies 2, 3, 5
• Never assume a wide complex tachycardia is SVT with aberrancy—always treat as VT unless definitively proven otherwise 3, 4
• Never use calcium channel blockers empirically for wide complex tachycardia 1, 3
• Never discharge a patient home with uncontrolled heart rate (target <100 bpm before discharge) 6
• Never fail to address the underlying metabolic or ischemic trigger 5, 6